The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease
Open accessAbstract
Alzheimer's disease and Parkinson's disease are associated with the cerebral accumulation of β-amyloid and α-synuclein, respectively. Some patients have clinical and pathological features of both diseases, raising the possibility of overlapping pathogenetic pathways. We generated transgenic (tg) mice with neuronal expression of human β-amyloid peptides, α-synuclein, or both. The functional and morphological alterations in doubly tg mice resembled the Lewy-body variant of Alzheimer's disease. These mice had severe deficits in learning and memory, developed motor deficits before α-synuclein singly tg mice, and showed prominent age-dependent degeneration of cholinergic neurons and presynaptic terminals. They also had more α-synuclein-immunoreactive neuronal inclusions than α-synuclein singly tg mice. Ultrastructurally, some of these inclusions were fibrillar in doubly tg mice, whereas all inclusions were amorphous in α-synuclein singly tg mice. β-Amyloid peptides promoted aggregation of α-synuclein in a cell-free system and intraneuronal accumulation of α-synuclein in cell culture. β-Amyloid peptides may contribute to the development of Lewy-body diseases by promoting the aggregation of α-synuclein and exacerbating α-synuclein-dependent neuronal pathologies. Therefore, treatments that block the production or accumulation of β-amyloid peptides could benefit a broader spectrum of disorders than previously anticipated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“The hαSyn/hAPP model recapitulated many of the clinical symptoms and pathology of AD-LBV.”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Further evidence of a link between αSyn and Aβ pathology was offered from studies using mice expressing wt human αSyn (hαSyn) and human APP (hAPP) (hαSyn/hAPP).”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
In the citing paper
“Compared to animals expressing only hαSyn or hAPP, the hαSyn/hAPP animals had marked cholinergic neuron loss, intraneuronal LRP, florid Aβ plaques, exhibited marked motor dysfunction and had significant learning and memory deficits [198].”
From α-synuclein in the pathophysiology of Alzheimer’s disease (2019) · cites this paper as [198]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Alzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Self-citationMcKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
Games, D., Adams, D., Alessandrini, R., Barbour, R., Borthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., Gillespie, F., et al. (1995) · Nature · doi:10.1038/373523a0 · Cited by 2,516
Self-citationA Drosophila model of Parkinson's disease
Feany, M. Β., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,157
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,073
Flagged first, then by citations
Research works printed but not linked: 3
- R D Terry, R Katzman, K L Bick, S S Sisodia Alzheimer Disease (Lippincott, Philadelphia, 1999).
- A Takeda, M Mallory, M Sundsmo, W Honer, L Hansen, E Masliah Am J Pathol 152, 367–372 (1998).
- D Van Gool, B De Strooper, F Van Leuven, R Dom Dementia 6, 63–68 (1995).
Cited by
Sorted by citations
Items 301–400 of 607
Zhang, L., Yu, S., Zhang, R., Xing, Y., Li, Y., & Li, L. (2013) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-120260 · Cited by 37
Klein, C., Mathis, C., Leva, G., Patte‐Mensah, C., Cassel, J., Maître, M., & Mensah‐Nyagan, A. G. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.003 · Cited by 36
Alvarado, J. C., Fuentes‐Santamaría, V., Henkel, C. K., & Brunso‐Bechtold, J. K. (2004) · The Journal of Comparative Neurology · doi:10.1002/cne.11038 · Cited by 36
Stanca, S., Rossetti, M., & Bongioanni, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813880 · Cited by 35
Mougenot, A.-L. J., Bencsik, A. A., Nicot, S., Vulin, J., Morignat, E., Verchère, J., Bétemps, D., Lakhdar, L., Legastelois, S., & Baron, T. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318217d95f · Cited by 36
Fuentes‐Santamaría, V., Alvarado, J. C., Henkel, C. K., & Brunso-Bechtold, J. K. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.07.026 · Cited by 34
Lu, Z., Wang, J., Li, M., Liu, Q., Wei, D., Yang, M., & Kong, L. (2014) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2014.09.006 · Cited by 35
Mild cognitive impairment in Parkinson's disease: current view
Jellinger, K. A. (2024) · Frontiers in Cognition · doi:10.3389/fcogn.2024.1369538 · Cited by 40
Yu-Feng, S., Han, Y., Su, Y.-T., Yang, J., & Yu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130130 · Cited by 33
Kallhoff, V., Peethumnongsin, E., & Zheng, H. (2007) · Molecular Neurodegeneration · doi:10.1186/1750-1326-2-6 · Cited by 33
Jellinger, K. A. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.05.024 · Cited by 34
Masliah, E., & Hashimoto, M. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00029-3 · Cited by 33
Self-citationAmyloid Imaging in Alzheimer’s Disease and Other Dementias
Fodero‐Tavoletti, M. T., Cappai, R., McLean, C., Pike, K. E., Adlard, P. A., Cowie, T., Connor, A. R., Masters, C. L., Rowe, C. C., & Villemagne, V. L. (2009) · Brain Imaging and Behavior · doi:10.1007/s11682-009-9067-2 · Cited by 33
Blomqvist, M. E.-L., Silburn, P. A., Buchanan, D. D., Blennow, K., Mellick, G. D., Brookes, A. J., Andreasen, N., Pedersen, N. L., & Prince, J. A. (2004) · Neurogenetics · doi:10.1007/s10048-004-0173-4 · Cited by 31
Effects of Lewy body disease and Alzheimer disease on brain atrophy and cognitive dysfunction
Kang, S. W., Jeon, S., Yoo, H. S., Chung, S. J., Lee, P. H., Sohn, Y. H., Yun, M., Evans, A. C., & Ye, B. S. (2019) · Neurology · doi:10.1212/wnl.0000000000007373 · Cited by 31
Heterotypic interactions in amyloid function and disease
Konstantoulea, K., Louros, N. N., Rousseau, F., & Schymkowitz, J. W. H. (2021) · FEBS Journal · doi:10.1111/febs.15719 · Cited by 34
Charissé, D., Erus, G., Pomponio, R., Gorges, M., Schmidt, N., Schneider, C. B., Liepelt‐Scarfone, I., Riedel, O., Reetz, K., Schulz, J. B., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.020 · Cited by 31
Alpha- and beta-synuclein expression in Parkinson disease with and without dementia
Beyer, K., Ispierto, L., Latorre, P., TOLOSA, E. S., & Ariza, A. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.05.049 · Cited by 33
Jose, J. C., Chatterjee, P., & Sengupta, N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106883 · Cited by 32
Signs of cross-seeding: aortic medin amyloid as a trigger for protein AA deposition
Larsson, A., Malmström, S., & Westermark, P. (2011) · Amyloid · doi:10.3109/13506129.2011.630761 · Cited by 32
Resende, R., Marques, S., Ferreiro, E. B., Simões, I., Oliveira, C. R., & Pereira, C. (2013) · Neurochemical Research · doi:10.1007/s11064-013-0982-7 · Cited by 31
Gadhave, K., Gehi, B. R., Kumar, P., Xue, B., Uversky, V. N., & Giri, R. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03414-9 · Cited by 35
β-Amyloid PET and 123 I-FP-CIT SPECT in Mild Cognitive Impairment at Risk for Lewy Body Dementia
Chen, Q., Lowe, V. J., Boeve, B. F., Przybelski, S. A., Miyagawa, T., Senjem, M. L., Jack, C. R., Lesnick, T. G., Kremers, W. K., Fields, J. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011454 · Cited by 30
Mitochondrial dysfunction in Parkinson’s disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750811040032 · Cited by 30
Sierra, M., Gelpí, E., Martı́, M. J., & Compta, Y. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12308 · Cited by 30
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease
Shirvan, J. C., Clement, N. F., Ye, R., Katz, S. R., Schultz, A. P., Johnson, K. A., Gómez‐Isla, T., Frosch, M. P., Growdon, J. H., & Gomperts, S. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007855 · Cited by 31
α-Synuclein Aggregation and Modulating Factors
Paleologou, K. E., & El‐Agnaf, O. M. A. (2012) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-007-5416-4_6 · Cited by 33
The impact of genetic research on our understanding of Parkinson’s disease
Martin, I., Dawson, V. L., & Dawson, T. M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83002-x · Cited by 32
Microglia-driven inflammation induces progressive tauopathies and synucleinopathies
Lee, S. H., Bae, E.-J., Park, S. J., & Lee, S. (2025) · Experimental & Molecular Medicine · doi:10.1038/s12276-025-01450-z · Cited by 31
Mandler, M., Rockenstein, E. M., Overk, C., Mante, M., Florio, J. B., Adame, A., Kim, C., Santic, R., Schneeberger, A., Mattner, F., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.02.002 · Cited by 29
Self-citationBuchman, V. L., & Ninkina, N. N. (2008) · Neurotoxicity Research · doi:10.1007/bf03033857 · Cited by 29
Stav, A. L., Johansen, K. K., Auning, E., Kalheim, L. F., Selnes, P., Bjørnerud, A., Hessen, E., Aarsland, D., & Fladby, T. (2016) · npj Parkinson s Disease · doi:10.1038/npjparkd.2015.30 · Cited by 29
Thy1-ApoE4/C/EBPβ double transgenic mice act as a sporadic model with Alzheimer’s disease
Qian, Z., Wang, Z., Li, B., Meng, X., Kuang, Z., Li, Y., Yang, Y., & Ye, K. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02565-x · Cited by 28
Protein aggregation and prionopathies
Renner, M. L., & Melki, R. (2014) · Pathologie Biologie · doi:10.1016/j.patbio.2014.01.003 · Cited by 31
Daniele, S., Pietrobono, D., Fusi, J., Gerfo, A. L., Cerri, E., Chico, L., Iofrida, C., Petrozzi, L., Baldacci, F., Giacomelli, C., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00017 · Cited by 28
Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients
López, O. L., Kofler, J., Chang, Y., Berman, S., Becker, J. T., Sweet, R. A., Nadkarni, N. K., Patira, R., Kamboh, M. I., Cohen, A. D., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51135 · Cited by 28
Whiten, D. R., Brownjohn, P. W., Moore, S., De, S., Strano, A., Zuo, Y., Haneklaus, M., Klenerman, D., & Livesey, F. J. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa146 · Cited by 28
α-synuclein-assisted oligomerization of β-amyloid (1–42)
Chau, E., & Kim, J. R. (2022) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2022.109120 · Cited by 30
Interactions of amyloid coaggregates with biomolecules and its relevance to neurodegeneration
Murakami, K., & Ono, K. (2022) · The FASEB Journal · doi:10.1096/fj.202200235r · Cited by 28
Progress in Clinical Neurosciences: Parkinson's Disease with Dementia and Dementia with Lewy Bodies
Camicioli, R. M., & Fisher, N. (2004) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100002791 · Cited by 28
Molecular specializations of deep cortical layer analogs in songbirds
Nevue, A. A., Lovell, P. V., Wirthlin, M. E., & Mello, C. V. (2020) · Scientific Reports · doi:10.1038/s41598-020-75773-4 · Cited by 28
Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model
Lloyd, G. M., Dhillon, J.-K. S., Gorion, K.-M. M., Riffe, C. J., Fromholt, S., Xia, Y., Giasson, B. I., & Borchelt, D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00486-9 · Cited by 29
Inhibition of Polo-like kinase 2 ameliorates pathogenesis in Alzheimer’s disease model mice
Lee, J. S., Lee, Y., André, E. A., Lee, K. J., Nguyen, T., Feng, Y., Jia, N., Harris, B. T., Burns, M. P., & Pak, D. T. S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219691 · Cited by 30
Modèles animaux des maladies neuro-dégénératives
Langui, D., Lachapelle, F., & Duyckaerts, C. J. (2007) · médecine/sciences · doi:10.1051/medsci/2007232180 · Cited by 32
Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia
Kronimus, Y., Albus, A., Balzer‐Geldsetzer, M., Straub, S., Semler, E., Otto, M., Klotsche, J., Dodel, R. C., & Mengel, D. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164953 · Cited by 26
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
Fouka, M., Mavroeidi, P., Tsaka, G., & Xilouri, M. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.559791 · Cited by 27
Sharma, A., Muresanu, D. F., Patnaik, R., Menon, P. K., Tian, Z. R., Sahib, S., Nozari, A., Lafuente, J. V., Buzoianu, A. D., Skaper, S. D., et al. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.06.003 · Cited by 28
β-Amyloid and α-Synuclein Cooperate To Block SNARE-Dependent Vesicle Fusion
Choi, B.-K., Kim, J.-Y., Cha, M.-Y., Mook‐Jung, I., Shin, Y.-K., & Lee, N. K. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00087 · Cited by 27
RetractedAndringa, G., Du, F., Chase, T. N., & Bennett, M. C. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.10.1060 · Cited by 26
Familial associations of Alzheimer disease and essential tremor with Parkinson disease
Costello, S., Bordelon, Y. M., Bronstein, J. M., & Ritz, B. R. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02974.x · Cited by 26
Association of APOE with Parkinson disease age-at-onset in women.
Buchanan, D., Silburn, P., Prince, J., & Mellick, G. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.07.080 · Cited by 29
Shaw, C., & Wilson, J. M. B. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.08.001 · Cited by 26
Takamatsu, Y., Ho, G. J., Koike, W., Sugama, S., Takenouchi, T., Waragai, M., Wei, J., Sekiyama, K., & Hashimoto, M. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-016-0001-1 · Cited by 26
Self-citationA comprehensive screening of copy number variability in dementia with Lewy bodies
Kun‐Rodrigues, C., Orme, T., Carmona, S., Hernandez, D. G., Ross, O. A., Eicher, J. D., Shepherd, C. E., Parkkinen, L., Darwent, L., Heckman, M. G., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.019 · Cited by 28
Self-citationKoufos, E., Chang, E. H., Rasti, E. S., Krueger, E. E., & Brown, A. C. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00430 · Cited by 25
Feller, B., Fallon, A., Luo, W., Nguyen, P. T., Shlaifer, I., Lee, A. K., Chofflet, N., Yi, N., Khaled, H., Karkout, S., et al. (2023) · Cells · doi:10.3390/cells12071083 · Cited by 22
Noguchi‐Shinohara, M., & Ono, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210215 · Cited by 24
Disease-modifying therapeutic directions for Lewy-Body dementias
Zhang, Q., Kim, Y.-C., & Narayanan, N. S. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00293 · Cited by 26
Masliah, E., Rockenstein, E. M., Inglis, C. A., Adame, A., Bett, C. K., Lucero, M., & Sigurdson, C. J. (2012) · Prion · doi:10.4161/pri.19806 · Cited by 26
Self-citationMolecular Mechanisms of the Bindings between Non-Amyloid β Component Oligomers and Amylin Oligomers
Atsmon‐Raz, Y., & Miller, Y. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b07731 · Cited by 24
Compta, Y., Ezquerra, M., Muñoz, E., TOLOSA, E. S., Valldeoriola, F., Ríos, J., Cámara, A., Fernández, M., Buongiorno, M., & Martı́, M. J. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.10.015 · Cited by 24
The genetics of neurodegenerative diseases is the genetics of age-related damage clearance failure
Hardy, J., & Escott‐Price, V. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02911-7 · Cited by 25
The relationship between plasma biomarkers and amyloid PET in dementia with Lewy bodies
Donaghy, P. C., Firbank, M., Petrides, G. S., Lloyd, J. J., Barnett, N. A., Olsen, K., Heslegrave, A., Zetterberg, H., Thomas, A. J., & O'Brien, J. T. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.07.008 · Cited by 23
The Potential Regulators of Amyloidogenic Pathway of APP Processing in Alzheimer’s Disease
Krawczuk, D., Kulczyńska‐Przybik, A., & Mroczko, B. (2025) · Biomedicines · doi:10.3390/biomedicines13071513 · Cited by 28
Reciprocal Induction Between α-Synuclein and β-Amyloid in Adult Rat Neurons
Majd, S., Chegini, F., Chataway, T., Zhou, X., & Gai, W. (2012) · Neurotoxicity Research · doi:10.1007/s12640-012-9330-y · Cited by 22
Clinical and striatal dopamine transporter predictors of β-amyloid in dementia with Lewy bodies
Yoo, H. S., Lee, S., Chung, S. J., Lee, Y. H., Ye, B. S., Sohn, Y. H., Yun, M., & Lee, P. H. (2020) · Neurology · doi:10.1212/wnl.0000000000009168 · Cited by 22
Neuroprotection in Parkinson’s disease: love story or mission impossible?
Linazasoro, G. (2002) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2.3.403 · Cited by 22
Magnetic Resonance Imaging Markers for Cognitive Impairment in Parkinson’s Disease: Current View
Hou, Y., & Shang, H. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.788846 · Cited by 21
Amyloid Protein Cross-Seeding Provides a New Perspective on Multiple Diseases In Vivo
Ge, W., Deng, X., Shi, W., Lin, W.-J., Chen, L., Liang, H., Wang, X., Zhang, T., Zhao, F., Guo, W., et al. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.2c01233 · Cited by 24
Different MAPT haplotypes influence expression of total MAPT in postmortem brain tissue
Tauber, C. V. I., Schwarz, S. C., Rösler, T. W., Arzberger, T., Gentleman, S., Windl, O., Krumbiegel, M., Reis, A., Ruf, V., Herms, J. W., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01534-9 · Cited by 21
Wu, J., Ohlsson, M., Warner, E. A., Loo, K. K., Hoang, T. X., Voskuhl, R. R., & Havton, L. A. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.037 · Cited by 21
Kang, J. (2016) · Journal of Movement Disorders · doi:10.14802/jmd.16017 · Cited by 21
Modreanu, R., Cerquera‐Cleves, C., Martı́, M. J., Ríos, J., Sánchez‐Gómez, A., Cámara, A., Fernández, M., & Compta, Y. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.064 · Cited by 21
Zhu, M., Patel, S. H., & Han, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.03.013 · Cited by 21
Jellinger, K. A. (2007) · Springer eBooks · doi:10.1007/978-0-387-30377-2_15 · Cited by 22
The Relationship between Lewy Body Disease, Parkinson's Disease, and Alzheimer's Disease
Hardy, J. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07474.x · Cited by 21
Parkinson’s Genetics: Molecular Insights for the New Millennium
Skipper, L. M., & Farrer, M. J. (2002) · NeuroToxicology · doi:10.1016/s0161-813x(02)00038-4 · Cited by 21
Lewy Body Dementias: A Coin with Two Sides?
Milán-Tomás, Á., Fernández‐Matarrubia, M., & Rodríguez-Oroz, M. C. (2021) · Behavioral Sciences · doi:10.3390/bs11070094 · Cited by 24
Mouse Models of Cognitive Deficits Due to Alpha-Synuclein Pathology
Magen, I., & Chesselet, M. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11043 · Cited by 20
Palermo, G., Tommasini, L., Aghakhanyan, G., Frosini, D., Giuntini, M., Tognoni, G., Bonuccelli, U., Volterrani, D., & Ceravolo, R. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190323 · Cited by 20
Ermilova, I., & Lyubartsev, A. P. (2020) · RSC Advances · doi:10.1039/c9ra06424a · Cited by 20
Psychotropic and Neurotropic Activity
Vogel, H. G. (2007) · Springer eBooks · doi:10.1007/978-3-540-70995-4_6 · Cited by 22
Yedlapudi, D., Xu, L., Luo, D., Marsh, G. B., Todi, S. V., & Dutta, A. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55830-3 · Cited by 20
Comprehensive and Systematic Analysis of Gene Expression Patterns Associated with Body Mass Index
Joseph, P. V., Jaime-Lara, R. B., Wang, Y., Xiang, L., & Henderson, W. A. (2019) · Scientific Reports · doi:10.1038/s41598-019-43881-5 · Cited by 21
Tukacs, V., Mittli, D., Györffy, B. A., Hunyady-Gulyás, É., Hlatky, D., Tóth, V., Ravasz, L., Medzihradszky, F. K., Nyitrai, G., Czurkó, A., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72868-w · Cited by 19
Allopregnanolone enhances the neurogenesis of midbrain dopaminergic neurons in APPswe/PSEN1 mice
Zhang, P., Xie, M. Q., Ding, Y., Liao, M., Qi, S. S., Chen, S. X., Gu, Q., Zhou, P., & Sun, C. Y. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.01.019 · Cited by 18
The role of α-synuclein in neurodegeneration — An update
Jellinger, K. A. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0013-1 · Cited by 19
Jana, A. K., & Sengupta, N. (2014) · Soft Matter · doi:10.1039/c4sm01845a · Cited by 19
The role of APOE alleles in incident Parkinson’s disease. The Norwegian ParkWest Study
Vefring, H. K., Haugarvoll, K., Tysnes, O., Larsen, J. O., Kurz, M. W., & for the Norwegian ParkWest Study group (2010) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2010.01362.x · Cited by 19
Literature-Related Discovery (LRD)
Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A., Johnson, D., Lyons, T. J., & Wyatt, J. R. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada473438 · Cited by 19
Mitochondrial disfunction in Parkinson's disease
Бунеева, О. А., & Medvedev, A. E. (2011) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20115703246 · Cited by 18
Formation of Heterotypic Amyloids: α‐Synuclein in Co‐Aggregation
Bhasne, K., & Mukhopadhyay, S. (2018) · PROTEOMICS · doi:10.1002/pmic.201800059 · Cited by 17
Alzheimer's disease and related dementias
Hardy, J. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139087711.003 · Cited by 18
Kim, D., Paik, J. H., Shin, D.-W., Kim, H., Park, C., & Kang, J.-H. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.4.352 · Cited by 19
Windisch, M., Hutter‐Paier, B., Schreiner, E., & Wronski, R. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:24:1:155 · Cited by 18
Interactions of Volatile Anesthetics with Neurodegenerative-Disease-Associated Proteins
Carnini, A., Eckenhoff, M. F., & Eckenhoff, R. G. (2006) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2006.02.002 · Cited by 18
Lin, S., Leitao, A. D. G., Fang, S., Gu, Y., Barber, S., Gilliard-Telefoni, R., Castro, A., Sung, K., Shen, R., Florio, J. B., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106010 · Cited by 17
Self-citationConcomitant protein pathogenesis in Parkinson’s disease and perspective mechanisms
Han, Y., & He, Z. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1189809 · Cited by 18
Interaction of Proteins Involved in Neuronal Proteinopathies
Kulichikhin, K. Y., Malikova, O. A., Zobnina, A. E., Zalutskaya, N. M., & Rubel, A. A. (2023) · Life · doi:10.3390/life13101954 · Cited by 17
Génétique de la maladie d’Alzheimer : formes autosomiques dominantes
Guyant‐Maréchal, L., Campion, D., & Hannequin, D. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.10.019 · Cited by 20
Metadata
- Authors
- Masliah, E., Rockenstein, E., Veinbergs, I., Sagara, Y., Mallory, M., Hashimoto, M., & Mucke, L.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2001-09-25
- Volume
- 98
- Issue
- 21
- Pages
- 12245-12250
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC59799
- OpenAlex
- W2131710583
- Cited by
- 607
- References
- 56
- Citations by year
- 2026: 8 · 2025: 26 · 2024: 17 · 2023: 23 · 2022: 17 · 2021: 17 · 2020: 39 · 2019: 26 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 26 · 2014: 44 · 2013: 29 · 2012: 24
- FWCI
- 15.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2025-05-22)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (AG5131, 5r29ag010869-05, AG‐18440, AG11385, AG10869)
- National Institute on Aging (AG-11385, R37AG018440, R37AG011385, R01AG018440, P50AG005131, AG-5131, AG 18440, AG10869, R01AG011385)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, alpha-synuclein, Alzheimer's disease, Parkinson's disease, Lewy body disease, transgenic mice, neuronal inclusions, alpha-synuclein aggregation, cholinergic neuron degeneration, motor impairment, learning and memory impairment, presynaptic terminals
- MeSH terms
- Age Factors, Alzheimer Disease, Animals, Cell Line, Disease Models, Animal, Female, Humans, Learning Disabilities, Male, Memory Disorders, Mice, Transgenic, Nerve Tissue Proteins, Neurons, Parkinson Disease, Gene Expression, Amyloid beta-Peptides, Mice, Synucleins, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
